Table 2.
Change in potassium channel properties with different blockers.
| E10–E12 | E14–E16 | E19–E21 | ANOVA P | |
|---|---|---|---|---|
| Percentage change in Kv current (Ik) with bath application of Flx∧ (%) | ||||
| Ik reduction at −50 mV | 19.74 ± 23.03 (10) | 22.55 ± 16.65 (11) | 38.46 ± 20.96 (10) | P = 0.11 (Figure 7G) |
| Ik reduction at −10 mV | 66.64 ± 18.40 (10) | 38.81 ± 15.37 (11) | 42.66 ± 18.48 (10) | P < 0.01 (Figure 7F) |
| Ik reduction at +20 mV | 84.56 ± 11.35 (10) | 63.88 ± 11.10 (11) | 50.84 ± 16.80 (10) | P < 0.001 (Figure 7E) |
| Percentage change in action potential (AP) properties with bath application of TEA* (%) | ||||
| AP half width increase | 178.90 ± 143.30 (9) | 67.27 ± 22.53 (12) | 45.41 ± 39.40 (20) | P < 0.0001 (Figure 9B) |
| Max fall rate reduction | 66.73 ± 10.69 (9) | 46.51 ± 10.92 (12) | 37.98 ± 17.08 (20) | P < 0.001 (Figure 9C) |
| Threshold current reduction | 41.41 ± 24.45 (9) | 33.68 ± 10.01 (12) | 21.97 ± 11.49 (20) | P < 0.01 (Figure 9D) |
Flx∧, Fluoxetine (100 μM), Kv3.1-containing channel blocker. TEA*, Tetraethylammonium (1 mM), Kv3.1–3.4 blocker.